Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [531]

PRAME-targeted TCR therapy shows high response rates in metastatic uveal...

Dr Sapna Patel - University of Colorado Anschutz, Aurora, USA

PRAME-targeted TCR therapy shows high response rates in metastatic uveal melanoma ( Dr Sapna Patel - University of Colorado Anschutz, Aurora, USA )

ESMO 2025: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2025: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Adjuvant pembrolizumab in resected merkel cell carcinoma shows improved distant...

Dr Janice Mehnert - NYU Langone Health, New York, USA

Adjuvant pembrolizumab in resected merkel cell carcinoma shows improved distant metastasis-free survival ( Dr Janice Mehnert - NYU Langone Health, New York, USA )

IO102-IO103 cancer vaccine plus pembrolizumab demonstrates PFS benefit in...

Dr Inge Marie Svane - Copenhagen University Hospital, Copenhagen Denmark

IO102-IO103 cancer vaccine plus pembrolizumab demonstrates PFS benefit in advanced melanoma ( Dr Inge Marie Svane - Copenhagen University Hospital, Copenhagen Denmark )

MCED blood test demonstrates high specificity, strong predictive value, and...

Dr Nima Nabavizadeh - Oregon Health & Science University, Portland, USA

MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection ( Dr Nima Nabavizadeh - Oregon Health & Science University, Portland, USA )

Memorial Cancer Institute's Best of ASCO® 2025

Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA

Memorial Cancer Institute's Best of ASCO® 2025 ( Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA )

The hidden biology of addiction and cancer

Prof Raphael Cuomo - UC San Diego School of Medicine, San Diego, USA

The hidden biology of addiction and cancer ( Prof Raphael Cuomo - UC San Diego School of Medicine, San Diego, USA )

Encorafenib/binimetinib/nivolumab combo improves PFS in BRAF-mutant melanoma...

Dr Zeynep Eroglu - Moffitt Cancer Center, Tampa, USA

Encorafenib/binimetinib/nivolumab combo improves PFS in BRAF-mutant melanoma brain metastases ( Dr Zeynep Eroglu - Moffitt Cancer Center, Tampa, USA )

Enhanced pathologic response with neoadjuvant pembrolizumab plus vidutolimod in...

Dr Ahmad Tarhini - Moffitt Cancer Center, Tampa, USA

Enhanced pathologic response with neoadjuvant pembrolizumab plus vidutolimod in high-risk resectable melanoma ( Dr Ahmad Tarhini - Moffitt Cancer Center, Tampa, USA )

Cemiplimab reduces disease recurrence as adjuvant therapy for cutaneous...

Dr Danny Rischin - Peter MacCallum Cancer Centre, Melbourne, Australia

Cemiplimab reduces disease recurrence as adjuvant therapy for cutaneous squamous cell carcinoma ( Dr Danny Rischin - Peter MacCallum Cancer Centre, Melbourne, Australia )

Nivolumab/ipilimumab followed by BRAF/MEK inhibitors preferred sequence for...

Dr Michael B. Atkins - Georgetown Lombardi Comprehensive Cancer Center...

Nivolumab/ipilimumab followed by BRAF/MEK inhibitors preferred sequence for BRAF-positive advanced melanoma ( Dr Michael B. Atkins - Georgetown Lombardi Comprehensive Cancer Center, Washington, USA )

EGFR shows to be a promising therapeutic target in NF1 mutant melanoma

Dr Milad Ibrahim - NYU Langone Health, New York, USA

EGFR shows to be a promising therapeutic target in NF1 mutant melanoma ( Dr Milad Ibrahim - NYU Langone Health, New York, USA )

More from ecancer